We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
Read MoreHide Full Article
On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC - Free Report) , a leading distributor of health care products and services across the globe. The company currently carries a Zacks Rank #4 (Sell).
Over the past six months, Henry Schein has consistently traded below the Zacks categorized broader Medical - Dental Supplies industry. Unfavorable foreign currency exchange had an adverse impact on Henry Schein’s overall performance in the past few quarters. Also, escalating costs and expenses continue to be a drag on the company’s margins and put pressure on the bottom line. A tough competitive landscape and pricing pressure also weigh on Henry Schein’s stock.
In the absence of any growth catalyst, we expect the trend to continue in the days ahead. This apart, the recent emergence of group purchasing organizations (GPOs) and the consequent pricing pressure that they are exerting on single healthcare providers, like Henry Schein, might hamper the latter's business efficacy.
However, Henry Schein might gain from several trends in its end markets, one of them being customer demographics. According to a recent estimation, between 2015 and 2025, the population aged 45 and older will likely grow approximately 12%. This demographic trend is expected to boost the utilization of dental and medical products distributed by the company.
Penumbra gained 32.8% over the last one year compared to the S&P 500’s 20.4%. The company has an impressive four-quarter average earnings surprise of over 100%.
Neogen gained 27% in the past one year, way better than the S&P 500. The stock has an impressive long-term earnings growth of 16.7% for the next five years compared to the industry average of 15.2%.
Conatus Pharmaceuticals rallied 200.6%, much better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 12.5%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC - Free Report) , a leading distributor of health care products and services across the globe. The company currently carries a Zacks Rank #4 (Sell).
Over the past six months, Henry Schein has consistently traded below the Zacks categorized broader Medical - Dental Supplies industry. Unfavorable foreign currency exchange had an adverse impact on Henry Schein’s overall performance in the past few quarters. Also, escalating costs and expenses continue to be a drag on the company’s margins and put pressure on the bottom line. A tough competitive landscape and pricing pressure also weigh on Henry Schein’s stock.
In the absence of any growth catalyst, we expect the trend to continue in the days ahead. This apart, the recent emergence of group purchasing organizations (GPOs) and the consequent pricing pressure that they are exerting on single healthcare providers, like Henry Schein, might hamper the latter's business efficacy.
However, Henry Schein might gain from several trends in its end markets, one of them being customer demographics. According to a recent estimation, between 2015 and 2025, the population aged 45 and older will likely grow approximately 12%. This demographic trend is expected to boost the utilization of dental and medical products distributed by the company.
Key Picks
Better-ranked medical stocks are Penumbra, Inc. (PEN - Free Report) , Neogen Corporation (NEOG - Free Report) and Conatus Pharmaceuticals Inc. . Penumbra sports a Zacks Rank #1 (Strong Buy) while Neogen and Conatus carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra gained 32.8% over the last one year compared to the S&P 500’s 20.4%. The company has an impressive four-quarter average earnings surprise of over 100%.
Neogen gained 27% in the past one year, way better than the S&P 500. The stock has an impressive long-term earnings growth of 16.7% for the next five years compared to the industry average of 15.2%.
Conatus Pharmaceuticals rallied 200.6%, much better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 12.5%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>